Patents
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
03/2007
03/22/2007WO2005072308A3 Cgrp receptor antagonists
03/22/2007US20070066823 CCR9 inhibitors and methods of use thereof
03/22/2007US20070066821 Cyclopropyl amines as modulators of the histamine h3 receptor
03/22/2007US20070066820 Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
03/22/2007US20070066668 Isoxazolo derivatives
03/22/2007US20070066667 Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions
03/22/2007US20070066664 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses, materials for their synthesis
03/22/2007US20070066651 Pyrazoline derivatives useful for the treatment of cancer
03/22/2007US20070066617 Insecticidal and acaricidal activity for many agricultural insect pests, spider mites; endo- or ecto-parasiticide for mammals or birds; veterinary medicine; environmentally friendly
03/22/2007US20070066615 Heterocyclic compounds
03/22/2007US20070066613 (S)-2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid {1-[2-(3-ethoxy-propylamino) -ethyl]-1H-imidazol-4-yl}-amide, having beta-amyloid peptide production inhibitory activity, used for the treatment of neurodegenerative disorders such as Alzheimer's disease
03/22/2007US20070066612 N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimidin-5-yl]-2-cyclopentylacetamide; potassium ion channels modulators; epilepsy; seizure , anxiety , neuropathic pain and migraine pain disorders
03/22/2007US20070066611 Reacting 4-(4-nitrophenyl)-3-morpholinone with hydrogen in the presence of a hydrogenation catalyst, characterized in that reaction is effected in an aliphatic alcohol; precursor in synthesis of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
03/22/2007US20070066610 (S)-4-Bromo-3-[(2-2,3-dihydro-benzofuran-5-yl-acetyl)-hydrazono]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid [3-(2-hydroxymethyl-pyrrolidin-1-yl)-propyl]-amide; for treating conditions such as cancers and other cell proliferative disorders
03/22/2007US20070066609 Long acting beta-2-agonists and their use as medicaments
03/22/2007US20070066607 5-[R-2-(1S,2S-2-Cyclohexylcyclopentylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one, useful for treating conditions that are prevented or alleviated by activation of the adrenergic recptors
03/22/2007US20070066606 Benzylbenzimidazolyl derivatives
03/22/2007US20070066596 Pesticidal 5-substituted-oxalkylamino-1-arylpyrazole derivatives
03/22/2007US20070066591 Compounds for treatment of cell proliferation disorder and prevention of kinesins
03/22/2007US20070066590 Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism
03/22/2007US20070066585 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
03/22/2007US20070066584 Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: 1'-{[1-(4-Chlorophenyl)cyclo-pentyl]carbonyl}-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; antidiabetic agents
03/22/2007US20070066583 Monocyclic and bicyclic compounds and methods of use
03/22/2007US20070066573 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
03/22/2007US20070066488 Hetaryl-substituted pyrazolidindione derivatives with pesticidal characteristics
03/22/2007US20070062413 Novel anthrapyridone compound, water-based magenta ink composition and inkjet recording method
03/22/2007CA2622571A1 Methods of modulating neurotrophin-mediated activity
03/22/2007CA2622518A1 Thiazolinones and oxazolinones and their use as ptp1b inhibitors
03/22/2007CA2621370A1 Salicylate and gentisate salts of a piperazine compound
03/22/2007CA2620755A1 Glucuronate salt of a piperazine compound
03/21/2007EP1764366A2 Thrombin receptor antagonists
03/21/2007EP1764358A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain
03/21/2007EP1764134A2 Tetrahydroindolone and purine derivatives linked to arylpiperazines
03/21/2007EP1763531A1 Hepatitis c inhibitor peptide analogs
03/21/2007EP1763524A1 Indole derivatives and use thereof as kinase inhibitors
03/21/2007EP1763517A2 Pyrimidine derivatives as 11beta-hsd1 inhibitors
03/21/2007EP1763514A2 Cycloalkyl substituted pyrimidinediamine compounds and their uses
03/21/2007EP1763511A1 Phenoxyacetic acid derivatives as ppar agonists
03/21/2007EP1763303A1 Substituted pyridazine carboxamides and derivatives thereof
03/21/2007EP1451177B1 Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
03/21/2007EP1345943B1 Inhibitors of papilloma virus
03/21/2007EP1330460B1 Benzoxazinone derivatives, their preparation and use
03/21/2007EP1112270B1 Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
03/21/2007CN1934106A New process for the preparation of diazine derivatives
03/21/2007CN1934105A Aryl-substituted heterocycles, process for their preparation and their use as medicaments
03/21/2007CN1934104A Compounds for the treatment of diseases
03/21/2007CN1934102A New process for the preparation of diazine derivatives
03/21/2007CN1934100A Substituted quinazoline or pyridopyrimidine derivative
03/21/2007CN1934099A N-piperidine derivates as CCR3 modulators
03/21/2007CN1934088A 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
03/21/2007CN1934081A Novel benayl(idene)-lactam derivatives
03/21/2007CN1933839A Compounds and methods of use
03/21/2007CN1933838A Bipyridyl amides as modulators of metabotropic glutamate receptor-5
03/21/2007CN1933836A Heteroaryl piperidine glycine transporter inhibitors
03/21/2007CN1933830A Indole derivatives and use thereof as kinase inhibitors in particular ik. k.2 inhibitors
03/21/2007CN1305871C Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2a receptor-related disorders
03/21/2007CN1305858C Substituted azole compounds and their preparation and application
03/21/2007CN1305852C Diaryl ethers as opioid receptor antagonist
03/21/2007CN1305850C Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
03/21/2007CN1305847C 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
03/20/2007US7192974 Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents
03/20/2007US7192973 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
03/20/2007US7192967 Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents
03/20/2007US7192961 1-Carbonyl-4-(4-quinoline-)-piperazine or 1-carbonyl-4-[4-(1H-quinolin-2-{thio}one)-piperazine derivatives; retinopathy, adult respiratory distress syndrome, asthma, osteoarthritis, glomerulonephritis, psoriasis, rheumatoid arthritis, and toxic shock syndrome treatment
03/20/2007US7192957 3-Azabicyclo[3.1.0]hexane derivatives; human T-cell leukemia/lymphoma and lymphadenopathy associated virus; AIDS
03/20/2007US7192955 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
03/20/2007US7192954 Calcitonin Gene-Related Peptide (CGRP) antagonists for migraine and cluster headaches; 5'-acylamino-spiro[imidazolidine-4,2'-indane]-2,5-dione derivatives
03/20/2007US7192950 Psychological disorders; eating disorders; dietetics
03/20/2007US7192949 Anticarcinogenic and antiproliferative agents
03/20/2007CA2297326C Heterocyclic compound and antitumor agent containing the same as active component
03/20/2007CA2211320C 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
03/15/2007WO2007030559A2 1, 3-disubstituted indole derivatives for use as ppar modulators
03/15/2007WO2007029650A1 SYNTHESIS INTERMEDIATE FOR 1β-METHYLCARBAPENEM DERIVATIVE AND METHOD FOR PRODUCING SAME
03/15/2007WO2007029077A1 Substituted indazoles as inhibitors of phosphodiesterase type-iv
03/15/2007WO2007029062A2 Novel pyridine derivatives
03/15/2007WO2007029037A2 Class iia histone deacetylase (hdac) substrate
03/15/2007WO2007029036A2 Amino acid derivatives as histone deacetylase (hdac) inhibitors
03/15/2007WO2007029035A2 Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
03/15/2007WO2007029021A1 1,5-substituted tetrazoles as therapeutic compounds
03/15/2007WO2007028520A1 Iminooxazolidine derivatives and use thereof
03/15/2007WO2007028445A1 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
03/15/2007WO2007002220A3 Aminoacetamide acyl guanidines as beta-secretase inhibitors
03/15/2007WO2006136461A3 Non-steroidal progesterone receptor modulators
03/15/2007WO2006106437A8 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
03/15/2007US20070060752 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
03/15/2007US20070060629 Large conductance calcium-activated k channel opener
03/15/2007US20070060626 5-{4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-phenyl}-3H-[1,3,4]oxadiazol-2-one; agonists and antiagonists; demylination diseases; metabolic diseases; antidiabetic agents (type 2); syndrom X; asthma; osteoarthritis; lupus; antiinflammatory agents; cardiovascular disorders; cachexia
03/15/2007US20070060616 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds
03/15/2007US20070060591 Amine substituted (dihydro- or tetrahydro-)quinoline, pyranopyridine, thiapyranopyridine, or naphthyridine derivatives as chemokine receptor modulators; lymphadenopathy associated, human T-cell leukemia/lymphoma, and/or feline immunodeficiency virus infections
03/15/2007US20070060590 osteoporosis and fracture; Prostaglandin E2 derivatives specially EP4 receptor agonists; ethyl 3-{4-[(2-{3-oxo-4-[3-(trifluoromethyl)phenyl]butyl}-6-oxotetrahydropyridazin-1-yl)methyl]phenyl}acrylate
03/15/2007US20070060589 Inhibitors of protein arginine methyl transferases
03/15/2007US20070060585 2-[1-Phenyl-2-(2-trifluoromethyl-phenyl)-ethyl]-morpholine-4-carboxylic acid benzyl ester, for example; for the treatment of disturbances of vegetative function associated with affective, anxiety and cognitive disorders
03/15/2007US20070060584 Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
03/15/2007US20070060583 2-tert-Butyl-N,N-diethyl-1-{[1-methylpiperidin-2-yl]methyl}-1H-benzimidazole-5-carboxamide; cannabinoid receptors agonists; analgesic, anticarcinogenic, antiinflammatory, anxiolytic agent; neurodegenerative diseases; gastrointestinal and cardiovascular disorders
03/15/2007US20070060582 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
03/15/2007US20070060581 1-Sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands
03/15/2007US20070060580 (8-{4-[3-(5 -Fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one), for example; useful as modulator of one or more G-protein coupled receptors; for treating or lessening the severity of disorders selected from Parkinson's disease, psychoses depression, anxiety
03/15/2007US20070060573 Acyltryptophanols
03/15/2007US20070060571 e.g. 4-(5-(4-Chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl)benzenesulfonamide and nitric oxide donor (S-nitrosothiols, nitrites, nitrates, N-oxo-N-nitrosamines, sabstrate of nitric oxide synthase); analgesics, antiinflammatory agent, wound healing; gastrointestinal disorders; side effect reduction
03/15/2007US20070060569 Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors